Role of novel biomarkers in diabetic cardiomyopathy

doi:10.4239/wjd.v12.i6.685

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9624)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

630

WORD

239

HTML

5253

Figures (1-3)

664

Tables (1-1)

318

Sum=7104

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

380

Download

676

Sum=1056

Publishing Process of This Article

Item

Count

Browse

540

Download

924

Sum=1464

Jun 15, 2021 (publication date) through Jan 23, 2025

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Jun 15, 2021; 12(6): 685-705
Published online Jun 15, 2021. doi: 10.4239/wjd.v12.i6.685

Full Size Figure Download Figure

Figure 3 Molecular target of the soluble form of suppression of tumorigenicity 2. sST2: Soluble form of suppression of tumorigenicity 2; IL-33: Interleukin-33; ST2L: Suppression of tumorigenicity 2 ligand; T_H2: T helper lymphocyte type 2.

Citation: Kumric M, Ticinovic Kurir T, Borovac JA, Bozic J. Role of novel biomarkers in diabetic cardiomyopathy. World J Diabetes 2021; 12(6): 685-705
URL: https://www.wjgnet.com/1948-9358/full/v12/i6/685.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i6.685